Inventor · disambiguated record
Scott Moe
Also filed as: MOE SCOTT · MOE SCOTT T
29 granted patents·19 pending applications·1,245 citations·filing 1993–2025
97Inventor score
Top patents by PatentIndex Score
48 records- 0198US6660753B2Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonistsNPS PHARMA INC·Filed 2002·Granted Dec 9, 2003·160 cites·58 claims
- 0296US7112595B2Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonistsASTRAZENECA AB·Filed 2003·Granted Sep 26, 2006·92 cites·23 claims
- 0396US6211244B1Calcium receptor-active compoundsNPS PHARMA INC·Filed 1995·Granted Apr 3, 2001·251 cites·46 claims
- 0494US12202799B2Agents for differentiating stem cells and treating cancerMINERVA BIOTECHNOLOGIES CORP·Filed 2021·Granted Jan 21, 2025·2 cites·18 claims
- 0594US6429207B1Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseasesNPS PHARMA INC·Filed 2000·Granted Aug 6, 2002·67 cites·23 claims
- 0694US6011068ACalcium receptor-active moleculesBRIGHAM & WOMENS HOSPITAL·Filed 1994·Granted Jan 4, 2000·137 cites·103 claims
- 0793US6031003ACalcium receptor-active moleculesNPS PHARMA INC·Filed 1995·Granted Feb 29, 2000·151 cites·145 claims
- 0892US11931347B2Method of screening for agents for differentiating stem cellsMINERVA BIOTECHNOLOGIES CORP·Filed 2016·Granted Mar 19, 2024·5 cites·21 claims
- 0989US6001884ACalcium receptor-active moleculesNPS PHARMA INC·Filed 1995·Granted Dec 14, 1999·100 cites·44 claims
- 1089US5981599AInorganic ion receptor active compoundsNPS PHARMA INC·Filed 1997·Granted Nov 9, 1999·70 cites·27 claims
- 1188US12104170B2Methods for deriving dopaminergic neurons from pluripotent stem cellsMINERVA BIOTECHNOLOGIES CORP·Filed 2021·Granted Oct 1, 2024·2 cites·37 claims
- 1287US7501404B2Substituted azetidinonesDAIMED·Filed 2006·Granted Mar 10, 2009·21 cites·17 claims
- 1387US6071970ACompounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseasesNPS PHARMA INC·Filed 1995·Granted Jun 6, 2000·66 cites·185 claims
- 1481US2024409515A1Agents for differentiating stem cells and treating cancerMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Application pending·0 cites
- 1580US7053104B2Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseasesNPS PHARMA INC·Filed 2002·Granted May 30, 2006·9 cites·23 claims
- 1680US2024307359A1Method of screening for agents for differentiating stem cellsMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Application pending·0 cites
- 1777US6710088B2Inorganic ion receptor-active compoundsNPS PHARMA INC·Filed 2002·Granted Mar 23, 2004·8 cites·26 claims
- 1874US6617358B1Anticonvulsant and central nervous system-depressing bis(fluorophenyl)alkylamides and their usesNPS PHARMA INC·Filed 2000·Granted Sep 9, 2003·7 cites·19 claims
- 1974US2025121088A1Anti-muc1* antibody drug complexes and uses thereofMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Application pending·0 cites
- 2072US2025019651A1Methods for deriving dopaminergic neurons from pluripotent stem cellsMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Application pending·0 cites
- 2169US6342532B1Inorganic ion receptor active compoundsNPS PHARMA INC·Filed 1999·Granted Jan 29, 2002·22 cites·21 claims
- 2265US5298622ASpiroindane opiate analogsUNIV MINNESOTA·Filed 1993·Granted Mar 29, 1994·18 cites·17 claims
- 2365US2021087143A1Agents for differentiating stem cells and treating cancerMINERVA BIOTECHNOLOGIES CORP·Filed 2018·Application pending·0 cites
- 2464US5258384AS-11-hydroxy-10-methylaporphine and its biologically active salt forms as 5HT1A inhibitorsBRITISH TECH GROUP·Filed 1993·Granted Nov 2, 1993·9 cites·15 claims
- 2562US12491259B2Anti-variable MUC1* antibodies and uses thereofMINERVA BIOTECHNOLOGIES CORP·Filed 2023·Granted Dec 9, 2025·0 cites·20 claims
- 2662US7345048B2Heterocyclic compounds and uses thereof as D-alanyl-D-alanine ligase inhibitorsPLIVA D D·Filed 2002·Granted Mar 18, 2008·4 cites·22 claims
- 2762US2025255982A1Anti-muc1* antibody drug complexes and uses thereofMINERVA BIOTECHNOLOGIES CORP·Filed 2025·Application pending·0 cites
- 2861US2009143351A1Substituted azetidinonesDAIAMED·Filed 2009·Application pending·0 cites
- 2959US6017965ACompounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseasesNPS PHARMA INC·Filed 1996·Granted Jan 25, 2000·21 cites·35 claims
- 3057US2003199589A1Anticonvulsant and central nervous system-depressing bis (fluorophenyl) alkylamides and their usesNPS PHARMA INC·Filed 2003·Application pending·0 cites
- 3156US6306912B1Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseasesNPS PHARMA INC·Filed 1995·Granted Oct 23, 2001·12 cites·12 claims
- 3255US7268166B2Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseasesNPS PHARMA INC·Filed 2006·Granted Sep 11, 2007·0 cites·20 claims
- 3354US6750244B2Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseasesNPS PHARMA INC·Filed 2001·Granted Jun 15, 2004·1 cites·5 claims
- 3453US6051610ACompounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseasesNPS PHARMA INC·Filed 1999·Granted Apr 18, 2000·8 cites·24 claims
- 3549US7087765B2Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseasesNPS PHARMA INC·Filed 2004·Granted Aug 8, 2006·0 cites·6 claims
- 3649US2007207512A1Structure-based drug design methods for identifying d-ala-d-ala ligase inhibitors as antibacterial drugsPLIVA D D·Filed 2006·Application pending·0 cites
- 3749US2011034521A1Compounds and methods for treating zinc matrix metalloprotease dependent diseasesJACOBSON ALAN·Filed 2008·Application pending·0 cites
- 3848US2003119061A1Structure-based drug design methods for identifying D-Ala-D-Ala ligase inhibitors as antibacterial drugsFiled 2002·Application pending·0 cites
- 3948US2011190285A1Methods of treating a botulinum toxin related condition in a subjectABSOLUTE SCIENCE INC·Filed 2009·Application pending·0 cites
- 4048US2008090847A1Heterocyclic compounds and uses thereof as d-alanyl-d-alanine ligase inhibitorsPLIVA D D·Filed 2007·Application pending·0 cites
- 4148US2021299109A1Agents for treating cancer and methods for identifying said agentsMINERVA BIOTECHNOLOGIES CORP·Filed 2018·Application pending·0 cites
- 4245US2010144698A1Substituted azetidinonesDAIAMED·Filed 2010·Application pending·0 cites
- 4345US2006189661A1Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonistsWAGENEN BRADFORD V·Filed 2006·Application pending·0 cites
- 4442US6211245B1Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseasesNPS PHARMA INC·Filed 1998·Granted Apr 3, 2001·2 cites·45 claims
- 4540US2004039014A1Methods and compounds for treating depression and other disordersNPS PHARMA INC·Filed 2001·Application pending·0 cites
- 4639US2006025477A1Analogs of isovaleramide, a pharmaceutical composition including the same, and a method of treating central nervous system conditions or diseasesARTMAN LINDA D·Filed 2005·Application pending·0 cites
- 4730US2003166645A1Novel nitrofuran-containing heterocyclic compounds and uses thereofFiled 2002·Application pending·0 cites
- 4825US8586552B24,6-substituted 2,5-dideoxystreptamine aminoglycoside antibioticsSELECTX PHARMACEUTICALS INC·Filed 2013·Granted Nov 19, 2013·0 cites·25 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →